Ozempic (semaglutide) is a prescription medication initially approved for adults with type 2 diabetes to improve blood sugar control and reduce cardiovascular risks1 . While it is not officially approved for weight loss, its active ingredient, semaglutide, is recognized for significant weight reduction effects, particularly under the brand name Wegovy1 . The surge in demand for Ozempic has raised questions about eligibility, access, and alternatives for patients seeking treatment for obesity and related conditions2 .
Ozempic Eligibility Criteria
Ozempic is primarily approved as an injectable prescription medicine to improve blood sugar control in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in those with known heart disease3 . It is also used to reduce the risk of kidney disease worsening and kidney failure in adults with type 2 diabetes and chronic kidney disease3 .
For weight management, eligibility criteria focus on body mass index (BMI) and related health conditions. Typically, patients with a BMI of 30 or higher are considered eligible for Ozempic4 . It is also approved for use in people with a BMI of 27 or greater who have an accompanying overweight- or obesity-related condition, such as hypertension or osteoarthritis5 . Obesity is a well-established risk factor for conditions like knee osteoarthritis, where excess weight exacerbates symptoms and increases the need for surgical interventions such as total knee replacement6 . Ozempic has shown promise in reducing weight and potentially lowering the incidence of such surgeries in patients with osteoarthritis6 .
However, Ozempic is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 3. Patients should inform their healthcare providers about any history of pancreatitis, diabetic retinopathy, severe stomach problems, or planned surgeries before starting treatment3 .
- Nausea, vomiting, diarrhea, stomach pain, and constipation are the most common side effects3 .
- Serious risks include possible thyroid tumors, pancreatitis, changes in vision, low blood sugar, kidney problems, gallbladder issues, and allergic reactions3 .
- Use is not recommended during pregnancy or breastfeeding due to unknown safety3 .
How to Get an Ozempic Prescription
Obtaining an Ozempic prescription involves consultation with a healthcare provider who will evaluate eligibility based on medical history, BMI, and specific health conditions such as type 2 diabetes or obesity-related complications4 . Ozempic is administered once weekly via injection, with doses starting at 0.25 mg (a nontherapeutic dose) and increasing up to a maximum of 2 mg weekly7 . The injection can be given with or without food, on the same day each week, and at any time of day8 .
Patients should be instructed on proper injection techniques, including cleaning the skin with an alcohol swab and injecting into the stomach, thigh, or upper arm without injecting into a vein or muscle8 . Storage guidelines include refrigerating unused pens and discarding pens 8 weeks after first use8 .
Considering Costs
The high cost of Ozempic and other anti-obesity medications (AOMs) presents a significant barrier for many patients. These drugs typically range from $900 to $1,400 per month, with variable insurance coverage9 . Insurance authorization rates for Ozempic have declined recently, with some reports indicating coverage as low as 25% for certain patients2 . This financial burden may exacerbate health disparities, especially since lifelong use is often necessary to maintain benefits9 .
Insurance coverage and clinical appropriateness largely determine access to Ozempic prescriptions. Patients with type 2 diabetes and severe obesity are prioritized for treatment over those seeking weight loss for cosmetic reasons2 . Physicians must balance clinical needs with medication inventory and insurance policies when prescribing Ozempic10 .
“The high costs of anti-obesity drugs and the need for lifelong use pose significant financial challenges, which could worsen health disparities.”
— Robert Klitzman, Columbia University9
Current Ozempic Shortage Status
Since 2022, Ozempic and other semaglutide injection products have experienced supply shortages due to unprecedented demand11 . The FDA has confirmed that the shortage is now resolved as of early 2025, with manufacturers able to meet national demand12 . However, real-world analyses reveal that over half of patients prescribed GLP-1 receptor agonists, including Ozempic, experienced at least one medication disruption, often related to insurance coverage limitations or supply issues10 .
Patients who maintained continuous therapy without disruptions achieved greater weight loss (17% at 12 months, 18.6% at 24 months) compared to those with interruptions (15.7% at 12 months, 15.5% at 24 months) 10. Despite these challenges, patients meeting clinical criteria for obesity and metabolic health treatment were generally able to access GLP-1 therapies10 .
“There's also a risk that the excitement about these new medications might overshadow crucial public health efforts focused on prevention and lifestyle changes.”
— Robert Klitzman, Columbia University9
Falsified Medication
The surge in Ozempic's popularity has led to increased scrutiny over counterfeit products. Falsified Ozempic medications have caused life-threatening adverse effects, including hypoglycemic shock, nausea, coma, seizures, and infections2 . The FDA and World Health Organization have issued warnings about counterfeit Ozempic containing harmful substances or incorrect dosages2 .
Patients are strongly advised to obtain Ozempic only through licensed healthcare providers and pharmacies to avoid counterfeit risks. Compounded drugs are not FDA-approved and may not meet safety and efficacy standards11 .
Research shows that discontinuing Ozempic often leads to regaining two-thirds of lost weight within one year, highlighting the need for ongoing treatment and lifestyle changes2 .
The FDA has clarified policies to stabilize the national GLP-1 supply and emphasizes that only FDA-approved drugs undergo rigorous review for safety and quality. Patients should be cautious of non-approved compounded versions to avoid serious health risks11 2.
Ozempic Alternative Medications
The global interest in semaglutide and related GLP-1 receptor agonists has grown exponentially, especially in countries such as the United States, Canada, Australia, Brazil, and Ireland13 . Alongside Ozempic, other medications like Wegovy, Saxenda, and Mounjaro have gained attention for weight management14 .
Wegovy, which contains a higher dose of semaglutide than Ozempic, is FDA-approved specifically for long-term weight management and has demonstrated weight loss percentages exceeding those of Ozempic2 . These alternatives may be preferred for patients primarily seeking obesity treatment rather than diabetes management2 .
However, the increased demand for these medications has contributed to supply challenges and raised concerns about adverse drug reactions, which have steadily increased over recent years, peaking in 202413 . Potential risks of anti-obesity medications include gastrointestinal side effects, pancreatitis, kidney and gallbladder issues, and the possibility of triggering eating disorders9 .
| Aspect | Details | Citation |
|---|---|---|
| Approved Use | Type 2 diabetes management and cardiovascular risk reduction | 3 |
| Weight Loss Use | Off-label for Ozempic; FDA-approved for Wegovy | 12 |
| Eligibility Criteria | BMI ≥ 30 or BMI ≥ 27 with obesity-related conditions | 54 |
| Dosage | Weekly injection, 0.25 mg starting dose, max 2 mg | 78 |
| Common Side Effects | Nausea, vomiting, diarrhea, stomach pain, constipation | 3 |
💡 Did You Know?
Anti-obesity medications are now prescribed to an estimated 6% of Americans and are being explored for benefits beyond weight loss, including heart disease and Alzheimer's9 .
Ozempic Prescription Summary
Ozempic (semaglutide) is a weekly injectable prescription medication approved for adults with type 2 diabetes to improve glycemic control and reduce cardiovascular and kidney risks3 . While not FDA-approved for weight loss, its active ingredient is effective for this purpose under the brand Wegovy1 . Eligibility for Ozempic generally requires a BMI of 30 or higher, or 27 with an obesity-related condition5 4.
Patients must be screened for contraindications such as thyroid cancer history and pancreatitis risk before starting treatment3 . The medication is administered once weekly with careful attention to injection technique and storage8 . Costs and insurance coverage remain significant barriers, and ongoing supply shortages have impacted consistent access, although the shortage is now resolved10 12.
Patients should avoid counterfeit medications and obtain Ozempic only through licensed providers2 . Alternatives like Wegovy offer higher-dose semaglutide for weight loss and may be considered based on clinical needs2 .
